ESR1 and neoplasm: It is not a coincidence that the guideline update for biomarkers suggested that testing for PIK3CA mutations should use samples from tumor tissue or ctDNA in plasma to determine eligibility for treatment with alpelisib plus fulvestrant, a selective estrogen receptor degrader.